and foreign firms. In recent years the story of the rapid growth of Chinese firms has held considerable allure for
investors, prompting a flurry of reverse mergers involving Chinese-based firms. With speed comes additional risk.
Shell company shareholders may simply be looking for investors to take over their liabilities, such as pending
litigation, safety hazards, environmental problems, and unpaid tax liabilities. To prevent the public shell’s
shareholders from dumping their shares immediately following the merger, investors are required to hold their
shares for a specific period of time. The recent entry of Chinese firms into the U.S. public equity markets illustrates
the potential for fraud. Of the 159 Chinese–based firms that have been listed since 2006 via a reverse merger, 36
have been suspended or have halted trading in the United States after auditors found significant accounting issues.
Eleven more firms have been delisted from major U.S. stock exchanges.
Huiheng Medical (Huiheng) is one such firm that came under SEC scrutiny, having first listed its shares on the
over-the-counter (OTC) market in early 2008. The firm claimed it was China’s leading provider of gamma-ray
technology, a cancer-fighting technology, and boasted of having a strong order backlog and access to Western
management expertise through a joint venture. What follows is a discussion of how the firm went public and the
participants in that process. The firms involved in the reverse merger process included Mill Basin Technologies
(Mill), a Nevada incorporated and publicly listed shell corporation, and Allied Moral Holdings (Allied), a privately
owned Virgin Islands company with subsidiaries, including Huiheng Medical, primarily in China. Mill was the
successor firm to Pinewood Imports (Pinewood), a Nevada-based corporation, formed in November 2002 to import
pine molding. Ceasing operations in September 2006 to become a shell corporation, Pinewood changed its name to
Mill Basin Technologies. The firm began to search for a merger partner and registered shares for public trading in
2006 in anticipation of raising funds.
The reverse merger process employed by Allied, the privately owned operating company and owner of Huiheng,
to merge with Mill, the public shell corporation, early in 2008 to become a publicly listed firm is described in the
following steps. Allied is the target firm, and Mill is the acquiring firm.
Step 1. Negotiate terms and conditions: Premerger, Mill and Allied had 10,150,000 and 13,000,000 common
shares outstanding, respectively. Mill also had 266,666 preferred shares outstanding. Mill and Allied agreed to a
merger in which each Allied shareholder would receive one share of Mill stock for each Allied share they held. With
Mill as the surviving entity, former Allied shareholders would own 96.65% of Mill’s shares, and Mill’s former
shareholders would own the rest.
Step 2. Recapitalize the acquiring firm: Prior to the share exchange, shareholders in Mill, the shell corporation,
recapitalized the firm by contributing 9,700,000 of the shares they owned prior to the merger to Treasury stock,
effectively reducing the number of Mill common shares outstanding to 450,000 (10,150,000 – 9,700,000). The
objective of the recapitalization was to limit the total number of common shares outstanding postmerger in order to
support the price of the new firm’s shares. Such recapitalizations often are undertaken to reduce the number of
shares outstanding following closing in order to support the combined firms’ share price once it begins to trade on a
public exchange.4 The firm’s earnings per share are increased for a given level of earnings by reducing the number
of common shares outstanding.
Step 3. Close the deal: The terms of the merger called for Mill (the acquirer) to purchase 100% of the outstanding
Allied (the target) common and preferred shares, which required Mill to issue 13,000,000 new common shares and
266,666 new preferred shares. All premerger Allied shares were cancelled. Mill Basin Technologies was renamed
Huiheng Medical, reflecting potential investor interest at that time in both Chinese firms and in the healthcare
industry. See Exhibit 10.4 for an illustration of the premerger recapitalization of Mill, the postmerger equity
structure of the combined firms, and the resulting ownership distribution.
While Huiheng traded as high as $13 in late 2008, it plummeted to $1.60 in early 2012, reflecting the failure of
the firm to achieve any significant revenue and income in the cancer market, an inability to get an auditing firm to
approve their financial statements, and the absence of any significant order backlog. Having reported net income as
high as $9 million in 2007, just prior to completing the reverse merger, the firm was losing money and burning
4 Without the reduction in Mill’s premerger shares outstanding, total shares outstanding postmerger would have
been 23,150,000 [10,150,000 (Mill shares premerger) + 13,000,000 (Allied shares premerger)] rather than the
13,450,000 after the recapitalization.